COMMUNIQUÉS West-GlobeNewswire

Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences
22/05/2025
CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting [...]
ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares
22/05/2025
Purified Cortrophin Gel is the only ACTH therapy approved by the FDA for the treatment of acute gout flares Trial to be conducted by Dr. Hyon Choi at Massachusetts General Hospital and will compare the safety and [...]
Disclosure of voting rights at AGM in Vistin Pharma ASA
22/05/2025
Oslo, Norway, 22 May 2025 In relation to the Annual General Meeting in Vistin Pharma ASA (OSE: VISTN), on the 22th of May, the Company's Chair of the Board, Øyvin Brøymer, has received open proxies to represent a total [...]
PCI Biotech: Minutes of Annual General Meeting 2025
22/05/2025
Oslo, 22 May 2025. The Annual General Meeting in PCI Biotech Holding ASA took place today, 22 May 2025. All the matters on the agenda were approved and the minutes of the Annual General Meeting are attached to this [...]
Orion to host Capital Markets Day today, 22 May 2025, in Helsinki
22/05/2025
ORION CORPORATION INVESTOR NEWS 22 MAY 2025 at 10.15 EEST Orion to host Capital Markets Day today, 22 May 2025, in Helsinki Orion hosts its Capital Markets Day for analysts, institutional investors, bankers, and media [...]
CheqUp and WeightWatchers Announce Strategic Partnership to Support Growing Use of GLP-1 Medications in the UK
22/05/2025
Partnership Provides CheqUp Members Access to WeightWatchers’ Proven GLP-1 Companion Programme to Aid in Achieving Superior and Sustainable Results CHIPPENHAM, England, May 22, 2025 (GLOBE NEWSWIRE) -- CheqUp , one of [...]
LIfT BioSciences presents preclinical data on its first-in-class Immunomodulatory Alpha Neutrophils at American Society of Gene & Cell Therapy 28th Annual Meeting, showcasing its versatility in diseases beyond oncology
22/05/2025
London, 22 May 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today announces that preclinical data showing the wider therapeutic [...]
IBA Business Update Q1 2025
22/05/2025
Year starting on track Louvain-la-Neuve, Belgium, 22 May 2025 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its business update for the first quarter of 2025. [...]
IBA déclaration intermédiaire - premier trimestre 2025
22/05/2025
Début d’année conforme aux attentes Louvain-la-Neuve, Belgique, le 22 mai 2025 - IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules, publie aujourd'hui la revue [...]
Clue Reaches 1 Million Paid Subscribers, Cementing Position as Leading Data-Driven Women's Health Intelligence Platform
22/05/2025
BERLIN, May 22, 2025 (GLOBE NEWSWIRE) -- Clue, the data-driven women's health intelligence platform, today announced it has reached 1 million paid subscribers, more than doubling its subscriber base in just over a year [...]
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline
22/05/2025
Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline Paris, May 22, 2025. Sanofi announced today that it has entered into an agreement [...]
Communiqué de presse : Sanofi va acquérir Vigil Neuroscience, Inc. et ajouter un nouveau médicament expérimental pour le traitement de la maladie d’Alzheimer à son portefeuille en neurologie
22/05/2025
Sanofi va acquérir Vigil Neuroscience, Inc. et ajouter un nouveau médicament expérimental pour le traitement de la maladie d’Alzheimer à son portefeuille en neurologie Paris, le 22 mai 2025. Sanofi annonce aujourd’hui [...]
Senseonics Holdings, Inc. Announces Closing of Public Offering, Including Exercise in Full of the Underwriters’ Option to Purchase Additional Shares, and Closing of Private Placement
21/05/2025
Public offering results in gross proceeds of $57.5 million Private placement results in gross proceeds of approximately $20.3 million GERMANTOWN, Md., May 21, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE [...]
Premier Health Reports 2025 Second Quarter Results
21/05/2025
MONTRÉAL, May 21, 2025 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA ) (the “ Company ”), a leading Canadian Healthtech company, announces it has filed its unaudited Quarterly Consolidated Financial [...]
Vaxart Announces Adjournment of Annual Meeting of Stockholders
21/05/2025
Meeting adjourned to June 2, 2025 at 8:30 a.m. Pacific Time Vaxart encourages all stockholders of record on March 26, 2025 who have not yet voted to do so by 11:59 p.m. Eastern Time on June 1, 2025 SOUTH SAN FRANCISCO, [...]
L’Assemblée Générale Mixte de Cellectis se tiendra le 26 juin 2025
21/05/2025
NEW YORK, 21 mai 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa technologie pionnière d’édition du génome TALEN® pour développer de [...]
Cellectis’ Annual Shareholders General Meeting to be Held on June 26, 2025
21/05/2025
NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell [...]
Longevity Health Holdings Announces Continued Nasdaq Listing to Complete Merger With 20/20 Biolabs
21/05/2025
PITTSBURGH, May 21, 2025 (GLOBE NEWSWIRE) -- Longevity Health Holdings, Inc. (Nasdaq: XAGE) (“XAGE,” the “Company,” “we,” “us,” or “our”), a company focused on extending human longevity and healthy aging through [...]
Olema Oncology to Participate in Upcoming Investor Conferences
21/05/2025
SAN FRANCISCO, May 21, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]

Pages